Alyssa Gracely, MD
Urology · Salisbury, MDNPI 1174934624
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (44.2%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Medtronic accounts for 65.4% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2020 at $10,076 and has fallen 91.5% since, to $854 in 2025.
Across 182 payments — averaging $124.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$15K
- Axonics, Inc.$2K
- Boston Scientific$1K
- Intuitive Surgical$1K
- Dornier Medtech America, Inc$475
- AbbVie$440
- plus $2K from 20 others
What the payments were for
- Speaking & faculty fees$3,56516%
- Grants$10,00044%
- Travel & lodging$1,7068%
- Food & beverage$6,34928%
- Education$1,0004%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(3 entities) | 28 | $14,794 |
| Axonics, Inc. | 29 | $2,166 |
| Boston Scientific | 21 | $1,408 |
| Intuitive Surgical | 2 | $1,029 |
| Dornier Medtech America, Inc | 1 | $475 |
| AbbVie(2 entities) | 15 | $440 |
| Bayer | 16 | $326 |
| Dendreon Pharmaceuticals LLC | 11 | $294 |
| Progenics Pharmaceuticals, Inc. | 6 | $215 |
| Coloplast | 10 | $210 |
| Caldera Medical, Inc | 1 | $174 |
| Merck | 7 | $153 |
| Sumitomo Pharma America, Inc. | 6 | $134 |
| Teleflex LLC | 5 | $126 |
| Endo Pharmaceuticals Inc. | 1 | $114 |
| Olympus America Inc. | 3 | $101 |
| Astellas Pharma US Inc | 5 | $93 |
| Johnson & Johnson | 2 | $91 |
| Novartis | 4 | $86 |
| Tempus AI, Inc | 2 | $49 |
| 180 Medical, Inc. | 2 | $39 |
| Urogen Pharma, Inc. | 1 | $31 |
| Tolmar Pharmaceuticals, Inc. | 1 | $23 |
| Laborie Medical Technologies Corp. | 1 | $18 |
| Myovant Sciences Inc. | 1 | $16 |
| Endo USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTIVA$10,000
- INTERSTIM$4,012
- Bulkamid$1,013
- Da Vinci Surgical System$1,000
- Axonics r-SNM System$905
- AMS$865
- Dornier MedTech$475
- Axonics$137
- BOTOX$125
- PYLARIFY$114
- XIAFLEX$114
How this compares
$22,620 in reported general payments places this provider in the 85th percentile of 274 urology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 359 | $369,257 |
| MyrbetriqMirabegron | 153 | $126,042 |
| Estradiol | 357 | $34,178 |
| Tolterodine Tartrate ErTolterodine Tartrate | 59 | $7,864 |
| Oxybutynin Chloride ErOxybutynin Chloride | 174 | $5,624 |
| Tamsulosin Hcl | 228 | $4,891 |
| Solifenacin Succinate | 48 | $4,606 |
| YuvafemEstradiol | 12 | $4,282 |
| Desmopressin Acetate | 45 | $2,850 |
| Methenamine Hippurate | 18 | $2,002 |
| Diazepam | 24 | $1,983 |
| NitrofurantoinNitrofurantoin Macrocrystal | 48 | $1,958 |
| Finasteride | 62 | $1,001 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 20 | $638 |
| Cephalexin | 53 | $560 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $134 | $369,257359 claims |
| Astellas Pharma US IncMyrbetriq | $93 | $126,042153 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 274 urology providers in Maryland.
Other urology in Salisbury
- Matthew AllawayCumberland$20.6M
- Benjamin LowentrittBaltimore$549K
- Julio DavalosGlen Burnie$490K
- Sankar KausikBel Air$375K
- Laura GiustoOwings Mills$367K
- Amin HeratiBaltimore$160K
- Rian DicksteinHanover$144K
- Max KatesBaltimore$139K
- Arthur BurnettBaltimore$132K
- Aaron WeinbergBaltimore$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.